ArticleHuman mutation2026
A Mitoxyperilysis-Related Single-Cell and Machine-Learning Framework Defines an Immune-Cold Melanoma Phenotype and a Robust Prognostic Signature.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitoxyperilysis is a mitochondria-dependent membrane lysis process driven by innate immune and metabolic cues, yet its clinical relevance in melanoma remains unclear. We analyzed single-cell RNA-seq data (GSE215120) to quantify a mitoxyperilysis-related score (MRS), resolve cell-type heterogeneity, and compare predicted cell-cell communication between MRS-high and MRS-low tumor states. MRS was robust across alternative scoring approaches and varied markedly across cell types and malignant subpopulations. Compared with MRS-low tumors, the MRS-high state exhibited increased predicted intercellular communication (740 vs. 448 interactions) and higher global interaction strength (18,989 vs. 10,652), suggesting a rewired tumor ecosystem. To translate these programs to bulk melanoma, we selected the top 150 genes most correlated with MRS and benchmarked 101 machine-learning strategies in TCGA-SKCM to derive prognostic models, followed by external validation in six independent GEO cohorts. A gradient boosting machine (GBM)-based signature showed the most consistent cross-cohort performance and reliably stratified overall survival. High riskScore was associated with reduced immune and stromal signals, higher tumor purity, and an immune-cold tumor microenvironment as estimated by multialgorithm deconvolution and ESTIMATE. As a representative model gene, GPR143 was upregulated in melanoma, was associated with worse survival, and its functional knockdown suppressed colony formation in melanoma cells. Collectively, this work establishes a novel integrative framework that-for the first time-connects single-cell-resolved mitoxyperilysis-associated transcriptional programs with large-scale multicohort machine-learning validation, thereby enabling both mechanistic interpretation of immunometabolic heterogeneity and clinically applicable risk stratification in melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.